BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 25390554)

  • 21. [Chemotherapy for GI and pancreatic NETs].
    Doi T
    Gan To Kagaku Ryoho; 2013 Jul; 40(7):838-42. PubMed ID: 23863723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
    Mateo J; Heymach JV; Zurita AJ
    Mol Diagn Ther; 2012 Jun; 16(3):151-61. PubMed ID: 22515658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors.
    Wiedenmann B; Pavel M; Kos-Kudla B
    Neuroendocrinology; 2011; 94(3):177-90. PubMed ID: 21893937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
    Boussaha T; Rougier P; Taieb J; Lepere C
    Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):134-41. PubMed ID: 23562338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.
    Yim KL
    Endocrine; 2011 Oct; 40(2):181-6. PubMed ID: 21870172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on novel therapies for pancreatic neuroendocrine tumors: 2013.
    Dimou A; Syrigos KN; Saif MW
    JOP; 2013 Jul; 14(4):377-80. PubMed ID: 23846931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis.
    Chiu CW; Nozawa H; Hanahan D
    J Clin Oncol; 2010 Oct; 28(29):4425-33. PubMed ID: 20823411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Drug therapy for neuroendocrine tumours].
    Tóth M
    Orv Hetil; 2013 Sep; 154(39):1556-64. PubMed ID: 24058101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
    Krug S; Gress TM; Michl P; Rinke A
    Digestion; 2017; 96(2):67-75. PubMed ID: 28728148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promising advances in the treatment of malignant pancreatic endocrine tumors.
    Jensen RT; Delle Fave G
    N Engl J Med; 2011 Feb; 364(6):564-5. PubMed ID: 21306243
    [No Abstract]   [Full Text] [Related]  

  • 31. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
    Ganetsky A; Bhatt V
    Ann Pharmacother; 2012 Jun; 46(6):851-62. PubMed ID: 22589450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment Patterns and Burden of Illness in Patients Initiating Targeted Therapy or Chemotherapy for Pancreatic Neuroendocrine Tumors.
    Broder MS; Chang E; Reddy SR; Neary MP
    Pancreas; 2017 Aug; 46(7):891-897. PubMed ID: 28697129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in the management of unresectable or metastatic pancreatic neuroendocrine tumors: chemotherapy, targeted therapy, hormonal treatment, and future directions.
    Bilici A
    Asian Pac J Cancer Prev; 2015; 16(6):2151-9. PubMed ID: 25824731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
    Chan JA; Kulke MH
    Surg Oncol Clin N Am; 2016 Apr; 25(2):423-37. PubMed ID: 27013373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pancreatic neuroendocrine tumors: entering a new era.
    Oberstein PE; Remotti H; Saif MW; Libutti SK
    JOP; 2012 Mar; 13(2):169-73. PubMed ID: 22406593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroendocrine tumors of the pancreas.
    Milan SA; Yeo CJ
    Curr Opin Oncol; 2012 Jan; 24(1):46-55. PubMed ID: 22080942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors.
    Pavel ME; Wiedenmann B
    Horm Metab Res; 2011 Nov; 43(12):844-53. PubMed ID: 22105475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging therapeutic options for advanced enteropancreatic neuroendocrine tumors.
    Dasanu CA; Majumder S; Gopal S; Stoica-Mustafa E; Trikudanathan G
    Expert Opin Pharmacother; 2012 Mar; 13(4):461-71. PubMed ID: 22292707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors.
    Mulvey CK; Bergsland EK
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):63-82. PubMed ID: 26614369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Molecular target therapy for gastroenteropancreatic neuroendocrine tumors].
    Inoue N; Komoto I; Awane M; Imamura M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():492-5. PubMed ID: 23513889
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.